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Streptokinase, a 47-kDa protein isolated and secreted by most group
A, C and G ß-hemolytic streptococci, interacts with and activates
human protein plasminogen to form an active complex capable of
converting other plasminogen molecules to plasmin. Our objective
was to compare five streptokinase formulations commercially avail-
able in Brazil in terms of their activity in the in vitro tests of euglobulin
clot formation and of the hydrolysis of the plasmin-specific substrate
S-2251™. Euglobulin lysis time was determined using a 96-well
microtiter plate. Initially, human thrombin (10 IU/ml) and streptoki-
nase were placed in individual wells, clot formation was initiated by
the addition of plasma euglobulin, and turbidity was measured at 340
nm every 30 s. In the second assay, plasminogen activation was
measured using the plasmin-specific substrate S-2251™. Streptase™
was used as the reference formulation because it presented the stron-
gest fibrinolytic activity in the euglobulin lysis test. The Unitinase™
and Solustrep™ formulations were the weakest, showing about 50%
activity compared to the reference formulation. All streptokinases
tested activated plasminogen but significant differences were ob-
served. In terms of total S-2251™ activity per vial, Streptase™ (75.7
± 5.0 units) and Streptonase™ (94.7 ± 4.6 units) had the highest
activity, while Unitinase™ (31.0 ± 2.4 units) and Strek™ (32.9 ± 3.3
units) had the weakest activity. Solustrep™ (53.3 ± 2.7 units) pre-
sented intermediate activity. The variations among the different for-
mulations for both euglobulin lysis test and chromogenic substrate
hydrolysis correlated with the SDS-PAGE densitometric results for
the amount of 47-kDa protein. These data show that the commercially
available clinical streptokinase formulations vary significantly in their
in vitro activity. Whether these differences have clinical implications
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Introduction
In 1933, Tillet and Garner (1) first de-
scribed the exogenous plasminogen activa-
tor isolated and secreted by most group A, C
and G ß-hemolytic streptococci. This activa-
tor was named “streptokinase” by Chris-
tensen and MacLeod (2). Streptokinase, a
47-kDa protein, interacts with the protein
plasminogen to form a streptokinase-plas-
minogen complex capable of converting other
plasminogen molecules to plasmin. Strep-
tokinase does not require fibrin for efficient
plasminogen activation in blood (3). It is a
catalytically inert bacterial protein that has
no structural homologues (4,5). Streptoki-
nase can form an activator complex with
plasmin, which contains a functional active
site, or with plasminogen (lys-plasminogen)
in which it induces non-proteolytically the
formation of a functional active site (5,6).
The success of the complex formed by
streptokinase as a therapeutic agent has been
attributed to its unique mechanism of fibrin-
dependent plasminogen activation. When
administered to humans, the streptokinase
activator complex rapidly generates plasmin
in the circulating blood at sites distant from
fibrin clots. This mechanism depletes the
plasminogen substrate and exhausts the clot-
dissolving (or fibrinolytic) potential of plas-
minogen (7-9).
Streptokinase is now a leading agent for
the treatment of acute myocardial infarction.
Approximately 400,000-500,000 patients
receive thrombolytic therapy per year world-
wide. Many investigators (10-15), based on
several randomized multicenter clinical tri-
als, recommend 1,500,000 IU as the appro-
priate dose for the treatment of an acute
myocardial infarction. From a clinical per-
spective, the possible effect of significant
deviations from the recommended dose is
unknown. Note that the assays reported here
were not the same as used for the recommen-
dation of 1,500,000 IU.
Five streptokinase preparations commer-
cialized in Brazil for clinical use by different
manufacturers were analyzed to determine
their activity, content and homogeneity.
Streptase™ was used as a reference mate-
rial. The activity of the samples was deter-
mined on the basis of euglobulin lysis time
and of a chromogenic assay using S-2251™.
The homogeneity of the protein content of
the samples was determined by SDS-PAGE.
The study revealed significant differences
among commercially available preparations




Five streptokinase preparations from dif-
ferent manufacturers, containing 1,500,000
IU per vial as a powder, were tested (Table
1). Five milliliters of cold Milli-Q water was
added to each flask to dissolve the solid.
Samples nominally containing 300,000 IU/
ml were frozen at -70ºC until use. During
analysis all solutions were immersed in ice.
Preparation of human plasma and euglobulin
fraction
Blood was obtained by venipuncture from
the antecubital vein of 2 healthy volunteers
at rest, with minimum stasis. Samples were
collected into a 0.1 volume of 3.8% sodium
citrate and plasma was prepared by centrifu-
Table 1. Streptokinase formulations for clinical use evaluated in the present study.
Name Streptokinase supplier Lot No.
Streptase Hoechst Marion Roussel S/A 2482601F
Unitinase Meizler Comércio Internacional S/A 717102
Solustrep Laboratório Químico Farmacêutico Bergamo Ltda. DK0456
Streptonase Blausiegel Ind. & Com. Ltda. KH07K150
Strek Libra Produtos Laboratoriais Ltda. 717102
These streptokinase preparations are commercially available in Brazil and are identi-
fied by the commercial name, manufacturer and specific lot number. All formulations
nominally contained 1,500,000 IU of fibrinolytic activity per vial.
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gation (2,000 g) for 15 min at 4oC. Plasma
samples were pooled and kept at -70oC until
use.
The plasma euglobulin fraction was pre-
pared by 10-fold dilution of citrated plasma
and acidification at pH 5.0 by the addition of
1% acetic acid. After standing for 1 h at 4oC
the diluted plasma was centrifuged (2,000 g)
for 15 min at 4oC. The precipitate was dis-
solved in 0.1 M Tris-HCl buffer, pH 7.4.
Euglobulin clot lysis assay
We used a 96-well microtiter plate assay
to determine the euglobulin lysis time (16-
18). Control samples were prepared by add-
ing 20 µl human thrombin (10 IU/ml) and 30
µl 0.1 M Tris-HCl buffer, pH 7.4, to indi-
vidual wells. Test samples were prepared by
adding 10 µl thrombin, 10 µl buffer and 20
µl streptokinase solution. Clot formation was
initiated by the addition of 150 µl of the
plasma euglobulin fraction. The turbidity in
the wells was measured as absorbance at
340 nm every 30 s for 20 min using a
SPECTRAmax Microplate Spectrophotom-
eter and the software SOFTmax PRO (Mo-
lecular Devices Corporation, Sunnyvale, CA,
USA). Each streptokinase dilution was as-
sayed in triplicate. To evaluate the effect of
the different streptokinases on euglobulin
lysis time, we used the software GraphPad
Prisma 3.0 to plot the log of streptokinase IU
against log of the area under the curve. Lin-
ear regression was applied and the efficiency
of each streptokinase formulation was com-
pared to the reference Streptase™.
To evaluate the streptokinase activity af-
ter storing the stock solution, the fibrinolytic
activity was also evaluated after 24 h at 4oC.
Chromogenic assay
Plasminogen activation by streptokinase
was assayed using the synthetic substrate S-
2251™ (Chromogenix-Instrumentation Lab-
oratory, Milan, Italy). S-2251™ is a chromo-
genic substrate for both plasmin and strep-
tokinase-activated plasminogen. The method
for the determination of activity is based on
the difference in absorbance between the
pNA formed and the original substrate. The
rate of pNA formation is measured at 405
nm and this photometric signal is directly
proportional to the plasmin activity, which
reflects the amount of functional plasmino-
gen originally present in the sample.
The reaction was performed using 96-
well plates. Control samples were prepared
by adding 20 µl 0.1 M Tris-HCl buffer, pH
7.4, 30 µl substrate S-2251 (0.6 mM) and
100 µl plasminogen solution (0.1 CU/ml). In
the test samples the reaction was performed
after addition of 20 µl streptokinase solution
tested at different concentrations (150 to 600
IU/ml), 30 µl S-2251 and 100 µl plasmino-
gen solution. The plate was immediately
placed in the plate reader previously heated
at 37ºC. The absorbance of the wells was
measured at 405 nm every 30 s for 30 min.
Plates were shaken for 3 s before reading the
absorbance using a SPECTRAmax Micro-
plate Spectrophotometer and the software
SOFTmax PRO. Each streptokinase dilution
was assayed a minimum of three times.
One unit was defined as the amount of
enzyme activity that converts 1 µmol of sub-
strate per minute per liter. Since the enzy-
matic activity is normally calculated using a
cuvette with 1 cm of optical path, we adapt-
ed the formula to the 96-well plate taking
into account a total reaction volume of 150
µl and an optical path of 0.4 cm. Under these
conditions, the extinction coefficient of pNA
is 3840 mol l-1 cm-1.
Polyacrylamide gel electrophoresis
Samples were prepared for SDS-PAGE
analysis by diluting 50 µl of each streptoki-
nase stock solution in 950 µl Milli-Q water.
Finally, 100 µl of the diluted streptokinase
solution was mixed with 100 µl of 2X Laem-
mli buffer (19). Samples were heated at 95oC
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for 4 min to complete the reaction with the
SDS and ß-mercaptoethanol and 20 µl of
each sample was loaded onto the stacking
gel. PAGE was performed using a discon-
tinuous system (19). Samples were initially
loaded and stacked in 4% polyacrylamide
gel (stacking gel). Proteins were resolved in
10% polyacrylamide gel (resolving gel). SDS
was used in combination with ß-mercapto-
ethanol to reduce disulfide bonds, denature
the proteins and make the proteins nega-
tively charged. Electrophoresis was con-
ducted at 20 mA per gel (100-200 V) until
the bromophenol blue marker reached the
bottom of the gel. Proteins were stained with
Coomassie brilliant blue solution (0.025%
Coomassie blue in 10% acetic acid) for at
least 1 h, then destained with 10% acetic
acid for 2 h. Mobility was plotted against the
molecular weight of standard proteins
(SigmaMarker Wide Range, Sigma, St. Louis,
MO, USA) using a semi-log scale and the
molecular weight of the proteins was esti-
mated by interpolation.
Densitometric analysis of the protein
bands was performed using the software
Scion Image for Windows (Scion Corpora-
tion, Frederick, MD, USA).
Protein quantification
Total protein concentration was deter-
mined with the QuantiPro™ BCA assay kit




Clot formation was observed immedi-
ately after starting the reaction and turbidity
increased until clot lysis was initiated by
activated plasmin. The resulting graph was a
hyperbole and the area under the curve in-
creased with decreasing streptokinase con-
centration. Since the lines obtained were not
perfectly parallel, we performed the com-
parison using 100 points covering the total
line length. The relative streptokinase activ-
ity is represented as the mean ± SD of these
100 points.
Streptase™ showed the strongest fibrino-
lytic activity in the euglobulin lysis test.
Unitinase™ and Solustrep™ were the weak-
est proteins, showing about 50% of the activity
of the Streptase™ formulation (Table 2). The
data show a more than 50% difference in
activity between the most active (Streptase™)
and least active (Unitinase™) streptokinase
preparations as measured by euglobulin clot
lysis. Streptokinase activity decreased dra-
matically after 24 h at 4oC (Table 2).
Table 2. Comparison of streptokinase activity measured by euglobulin lysis in five
clinical formulations.
Streptokinase Streptokinase activity (%) Loss of streptokinase
relative to Streptase activity after 24 h at 4ºC (%)
Streptase™ 100 62.0 ± 4.7
Streptonase™ 83.3 ± 15.8 63.3 ± 9.5
Strek™ 71.6 ± 15.6 70.2 ± 3.0
Solustrep™ 52.2 ± 10.6 49.9 ± 6.7
Unitinase™ 46.8 ± 2.4 59.0 ± 3.3
Activity was measured by the euglobulin lysis test and is reported as percent of the
activity present in the Streptase™ formulation. Data are reported as the mean ± SEM
for three independent experiments performed in duplicate. The data for the stability
study at 4oC for 24 h represent the total loss (%) of the fibrinolytic activity compared
to the values reported in the first column.
Table 3. Comparison of streptokinase activity measured by the hydrolysis of the
chromogenic peptide S-2251™.
Streptokinase Total units Ratio to the reference Streptase N
Streptonase™ 94.7 ± 4.6 1.25 16
Streptase™ 75.7 ± 5.0 1.00 14
Solustrep™ 53.3 ± 2.7 0.70 15
Strek™ 32.9 ± 3.3 0.43 14
Unitinase™ 31.0 ± 2.4 0.41 12
Plasminogen activation induced by streptokinase was measured spectrophotometri-
cally with S-2251™, a substrate for both plasmin and streptokinase-activated plasmin-
ogen. One unit is defined as the amount of enzyme activity that converts 1 µmol of
substrate per minute per liter. Each of the streptokinase formulations tested was
compared to the reference Streptase™. Results are reported as the mean ± SEM for
the number of determinations shown in the right column.
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Hydrolysis of S-2251™
All streptokinase preparations tested hy-
drolyzed the plasminogen-like synthetic pep-
tide substrate. However, the activity varied
amongst the streptokinase formulations, as
indicated in Table 3. Streptonase™ (94.7 ±
4.6 units/vial) and Streptase™ (75.7 ± 5.0
units/vial) were the most active formulations,
while Strek™ and Unitinase™ were the
weakest (32.9 ± 3.3 and 31.0 ± 2.4 units/vial,
respectively). Solustrep™ (53.3 ± 2.7 units/
vial) presented intermediate activity (Table 3).
SDS-PAGE
Electrophoretic analysis showed two
major bands. The upper band corresponded
to human albumin (~67 kDa) and was the
most prominent protein (Figure 1A). The
lower band was identified as the streptoki-
nase protein on the basis of its apparent
molecular mass of 47 kDa (data not shown),
Streptase™, Solustrep™ and Streptonase™
showed contaminating proteins of a wide
molecular mass range below 67 kDa. The
bands corresponding to Unitinase™ and
Strek™ were resolved into two components.
Densitometric analysis of protein bands
confirmed a significant variation in the
amount of both streptokinase and human
albumin protein in each formulation (Figure
1B). The total amount of albumin is only
indicated on the label of the following
formulations: Unitinase™ (195 mg),
Solustrep™ (200 mg) and Streptonase™ (200
mg). After protein quantitation by three in-
dependent determinations the variability ob-
served for total protein amount observed in
each flask agreed with the densitometric re-
sults: Unitinase™ (87.5 ± 8.5 mg),
Streptase™ (207.1 ± 9.8 mg), Solustrep™
(374.0 ± 32.1 mg), Streptonase™ (433.3 ±
47.2 mg), and Strek™ (107.8 ± 5.1 mg).
The amount of protein corresponding to
streptokinase is not indicated on the product
labels. The variations among the different
formulations for both euglobulin lysis test
and chromogenic substrate hydrolysis pre-
sented a close correlation with the densito-
metric data for the streptokinase main band
(Figure 1B).
The euglobulin lysis test and the chromo-
genic substrate assay presented similar re-
sults in ranking the streptokinase activity of
five commercial clinical preparations. This
suggests that either assay can be used to
determine streptokinase activity. The chro-
mogenic substrate assay has the advantage
of being fast and highly reproducible. In the
Figure 1. SDS-PAGE analysis of the protein content of five streptokinase formulations. A,
PAGE was performed using a 10% polyacrylamide gel in a discontinuous system at 20 mA
per gel (100-200 V). Proteins were stained with Coomassie brilliant blue. This result is
representative of four independent experiments. B, Densitometric analysis of the albumin
and streptokinase bands. The areas of the bands are reported in arbitrary units. Note that
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euglobulin test, the preparation of the eu-
globulin fraction is laborious and this mate-
rial has also the disadvantage of being un-
stable.
The present study revealed significant
differences among the commercially avail-
able streptokinase preparations. Only
Streptonase™ presented similar fibrinolytic
activity when compared to Streptase™. All
other streptokinases presented significantly
less fibrinolytic activity. There are also sig-
nificant densitometric differences regarding
protein content associated with the SDS-
PAGE band.
Whether these differences have clinical
consequences deserve further evaluation by
both medical professionals and regulatory
authorities.
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